L-Histidine ( DrugBank: Histidine, L-Histidine )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04764383
(ClinicalTrials.gov)
January 1, 202218/2/2021Histaminergic Basis of Fatigue in Multiple SclerosisHistaminergic Basis of Fatigue in Multiple SclerosisMultiple SclerosisDrug: L-Histidine;Drug: Placebo;Drug: LodosynUniversity of MiamiNULLWithdrawn18 Years60 YearsAll0Phase 2United States
2NCT03266965
(ClinicalTrials.gov)
March 23, 20184/7/2017Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachHistaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachMultiple SclerosisDrug: Carbidopa;Dietary Supplement: L-HistidineUniversity of MiamiUnited States Department of DefenseCompleted18 Years60 YearsAll18Phase 1United States